Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | jun proto-oncogene | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | jun protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Brugia malayi | bZIP transcription factor family protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus multilocularis | jun protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | retinoblastoma-binding protein 4 (rbbp4) | 0.0018 | 0.0018 | 0.0023 |
Echinococcus multilocularis | jun protein | 0.0101 | 1 | 1 |
Echinococcus granulosus | jun protein | 0.0101 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0082 | 0.774 | 1 |
Brugia malayi | hypothetical protein | 0.008 | 0.7409 | 0.7409 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.0089 | 0.8515 | 0.8515 |
Echinococcus multilocularis | Ankyrin | 0.0018 | 0.0018 | 0.0018 |
Echinococcus granulosus | Ankyrin | 0.0018 | 0.0018 | 0.0018 |
Schistosoma mansoni | hypothetical protein | 0.0082 | 0.774 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0101 | 1 | 1 |
Onchocerca volvulus | 0.008 | 0.7409 | 0.5 | |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.0089 | 0.8515 | 0.8515 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0101 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0099 | 0.9669 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 13.885 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the NFkB signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.4802 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the AP-1 signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 43.9083 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 49.2659 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 49.2659 uM | PubChem BioAssay: Tox21. qHTS assay for small molecule activators of the heat shock response signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 55.2773 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 61.5038 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.